With a month to go before his Dec. 1 start date as president of MD Anderson Cancer Center, Peter Pisters reflected on the challenges that await him in Houston.
Genentech announced FDA has accepted the company's supplemental Biologics License Application for Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of advanced ovarian cancer.
Immune Design said the European Medicines Agency has granted Orphan Drug Designation for G100 for the treatment of follicular non-Hodgkin's lymphoma. G100 has also been granted orphan drug designation by the FDA for the treatment of follicular non-Hodgkin's lymphoma.
The National Coalition for Cancer Survivorship presented its second annual Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care.
Stand Up To Cancer, joined by the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association, announced four teams of researchers who will focus on on cancers of the lung and pancreas using the new approach of “interception” of cancers at very early stages.
Stand Up To Cancer has awarded 10 SU2C Catalyst clinical trial projects in which researchers from more than 30 institutions collaborate across academic and corporate borders on clinical trials across a variety of cancers, in a program supported by industry.
Barbara McAneny received the Annual Achievement Award of the Association of Community Cancer Centers.
The National Comprehensive Cancer Network said its registration count has grown to more than one million users. By registering on the NCCN website, users are able to view and download all of the NCCN Clinical Practice Guidelines in Oncology free of charge for non-commercial use. According to the latest count, the number of registered users has grown to 1,013,449.
Fox Chase Cancer Center has partnered with Suburban Community Hospital to open the Fox Chase Cancer Center East Norriton Hospital Outpatient Center.
Xiongbin Lu was named the Vera Bradley Foundation Professor of Breast Cancer Innovation at Indiana University School of Medicine. He is also professor of medical and molecular genetics at IU School of Medicine and a member of the Experimental and Developmental Therapeutics research program at the Indiana University Melvin and Bren Simon Cancer Center.
